CHIP regulates aquaporin-2 quality control and body water homeostasis by Wu, Q. et al.
CHIP Regulates Aquaporin-2 Quality Control and Body
Water Homeostasis
Qi Wu ,1 Hanne B. Moeller,1 Donté A. Stevens,2 Rebekah Sanchez-Hodge,2,3
Gabrielle Childers,2,3 Marleen L.A. Kortenoeven,1 Lei Cheng,1 Lena L. Rosenbaek,1,4
Carrie Rubel,2 Cam Patterson,5 Trairak Pisitkun ,1,6 Jonathan C. Schisler,2,3 and
Robert A. Fenton1
1InterPrET Center, Department of Biomedicine, Aarhus University, Aarhus, Denmark; 2McAllister Heart Institute and
3Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;
4Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark; 5Presbyterian
Hospital/Weill-Cornell Medical Center, New York, New York; and 6Faculty of Medicine, Chulalongkorn University,
Bangkok, Thailand
ABSTRACT
The importance of the kidney distal convoluted tubule (DCT) and cortical collecting duct (CCD) is highlighted by
various water and electrolyte disorders that arise when the unique transport properties of these segments are
disturbed. Despite this critical role, little is known about which proteins have a regulatory role in these cells and
how these cells can be regulated by individual physiologic stimuli. By combining proteomics, bioinformatics, and
cell biology approaches, we found that the E3 ubiquitin ligaseCHIP is highly expressed throughout the collecting
duct; is modulated in abundance by vasopressin; interacts with aquaporin-2 (AQP2), Hsp70, and Hsc70; and can
directly ubiquitylate the water channel AQP2 in vitro. shRNA knockdown of CHIP in CCD cells increased AQP2
protein t1/2 andreducedAQP2ubiquitylation, resulting ingreater levelsofAQP2andphosphorylatedAQP2.CHIP
knockdown increased the plasma membrane abundance of AQP2 in these cells. Compared with wild-type con-
trols,CHIPknockoutmiceornovelCRISPR/Cas9micewithoutCHIPE3 ligaseactivityhadgreaterAQP2abundance
andaltered renalwater handling,withdecreasedwater intake andurine volume, alongsidehigher urineosmolality.
Wedidnotobserve significant changes inotherwater-or sodium-transportingproteins in thegene-modifiedmice.
In summary, these results suggest that CHIP regulates AQP2 and subsequently, renal water handling.
J Am Soc Nephrol 29: 936–948, 2018. doi: https://doi.org/10.1681/ASN.2017050526
Theabilityof thekidney tomaintainbodywaterbalance
andthesystemicconcentrationsofvarious ionsiscritical
formammals to survive under varyingfluid anddietary
intakes. To allow these homeostatic processes to be per-
formed simultaneously, the renal tubule has developed
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Significance Statement
The distal convoluted tubule (DCT) and cortical col-
lectingduct (CCD)playuniqueanddiverse roles inwater
and electrolyte handling, but little is known about the
unique subset of regulatory proteins in these cells. This
manuscript combines proteomics and bioinformatics to
identifydifferentially expressedproteins in theDCTand
CCD under various physiological stimuli. The different
regulatory proteinswithin each cell type likely infer their
unique transport properties. We show that one regu-
latory protein highly expressed in the CCD, the E3
ubiquitin ligase CHIP, modulates the function of the
water channel aquaporin-2 and plays a role in renal
water handling. Pharmaceutical modulation of CHIP
function could be a novel approach to treat various
water balance disorders.
Figure 1. Quantitative proteomic and bioinformatics of mpkDCT and mpkCCD cells reveal cell- and treatment-specific kinases, E3 ligases,
deubiquitylases (DUBs), transcription factors, and enriched functional annotations. (A) Volcano plots of quantification between mpkDCT and
mpkCCD under three conditions. (A) BH-FDR 1% cutoff was used to select the differential proteome between these two cell types. (B) Number
of mpkDCT-specific proteins under three conditions. (C) Number of mpkCCD-specific proteins under three conditions. (D) mpkDCT-specific
kinases, E3 ligases, DUBs, and TFs under three conditions. (E) mpkCCD-specific kinases, E3 ligases, DUBs, and TFs under three conditions. (F)
Heat maps of mpkDCT and mpkCCD cells illustrating highly enriched functional annotations under three conditions.
specialized epithelial cells that allow independent regulationof
water and solute excretion. Two examples of these epithelial
cells are the cells of the distal convoluted tubule (DCT) and
principal cells of the cortical collecting duct (CCD).1
The unique functions of DCT and CCD
cells are inferred, at least inpart, by the selective
expression and regulation of a variety of differ-
ent membrane-associated transport proteins.
For example, in DCT cells, there is expression
of the divalent cation transporters TRPV5,
NCX1,andTRMP6thatare essential formain-
taining calcium and magnesium homeostasis
and the thiazide-sensitive NaCl cotransporter
NCC that plays a central role in regulatedNaCl
reabsorption.2 In contrast, CCDprincipal cells
express a variety of aquaporin (AQP) wa-
ter channels that help maintain body water
balance.3
Despite differing transporter profiles, the
functions of DCT and CCD principal cells are
under tightregulationbysimilarhormones,such
as aldosterone, angiotensin II (AngII), and vaso-
pressin (AVP).2,4–6 Furthermore, transport pro-
teins, such as the epithelial sodium channel, the
chloride channel CLC-K2, and the potassium
channel ROMK, are localized to both cell
types.2,6–8 Therefore, critical to understanding
how DCT and CCD cells maintain a unique
transport profile but respond to similar hor-
mones is knowledge of the regulatory proteins
within each cell type that are responsible for
both modulating cell-specific gene expression
and also, determining hormone-selective
regulatory responses within individual cells.
In this study, to identify novel and unique
regulatory proteins important formodulation
ofDCTandCCDfunction,wedetermined the
differential proteome of kidney DCT cells
(mpkDCT)andCCDcells (mpkCCD),which
are extensively characterized models of DCT
cells and CCD principal cells.9–12 After exten-
sive bioinformatics and confirmatory in vivo
studies, we characterized the role of theCCD-
enriched E3 ubiquitin ligase C terminus of
Hsc70 Interacting Protein (CHIP) for modu-
lating the function of AQP2 and subsequent
renal water handling.
RESULTS
mpkDCT and mpkCCD Differential
Proteome Analyses
LC-MS/MS shotgun proteomics was used
to investigate the differential proteome be-
tween mpkDCTand mpkCCD under basal, [deamino-Cys1,
D-Arg8]vasopressin (dDAVP; a synthetic analog of AVP), and
AngII conditions (Supplemental Figure 1). Of 4000 quantifi-
able proteins in each condition, 1101, 1294, and 1566
Figure 2. Confirmation of DCT or CCD enriched proteins in vivo. (A) Confocal images
of mouse kidney sections immunolabeled for COP9 Signalosome Subunit 6 (CSN6),
USP32, FBXO2, and CHIP alongside the DCT- or CCD-expressed proteins NCC or
AQP2, respectively. (B) Immunoblotting of purified DCT cells (green fluorescent protein
positive [GFP+]) illustrates that mpkDCT-enriched proteins FBXO2, SMAD4, SIX4, and
FBXO29 are abundant in isolated DCT cells, whereas the mpkCCD-enriched proteins NRK1,
USP4, CSN6, and CHIP are predominantly identified in the GFP2 fraction (representing non-
DCT cells).
proteins passed the Benjamini–Hochberg FDR threshold of 1%




AngII.html) (Figure 1A, Supplemental Table 1; Supplemental Tables
1–6 can be downloaded from http://interpretdb.au.dk/database/
DCTCCDcomparison/download.html). Five hundred ninety-
four proteins were present in all conditions, representing the
shared and unchanged portion of the mpkDCT and mpkCCD
proteome. Another 287 proteins of higher abundance were iden-
tified in mpkDCT cells, and 307 proteins were identified in
mpkCCD cells (Supplemental Table 2); 1025 proteins were spe-
cific for mpkDCT (Supplemental Material discusses selection cri-
teria), and 1211 proteins were specific for mpkCCD (Figure 1, B
and C, Supplemental Table 3). Comparison of specific proteins
with a mouse kinome database (http://kinase.com/kinbase) de-
termined that ten and 22 kinases are selective for mpkDCT and
mpkCCD cells, respectively (Figure 1, D and E); 24 and 29 pro-
teinswith knownE3 ligase or E3 ligase adapter activity and six and
seven proteins with deubiquitylase activity13,14 were identified in
mpkDCTandmpkCCD cells, respectively (Figure 1, D and E). In
addition several transcription factors were identified (Figure 1, D
and E), but cross reference of these with matrix families for char-
acteristic genes expressed in the DCTor CCD (Supplemental Ta-
ble 4) indicated that only onematrix family, V$SIXF, seemed to be
highly specific. The abundances of several proteins were confirmed
usingWestern blotting of equal protein equivalents (Supplemental
Figure 2) isolated from a different cohort of cells cultured under
similar conditions (Supplemental Figures 3–5). Abundance ratios
derived from semiquantitative immunoblotting or MS were
highly similar, with Spearman correlations of 0.92, 0.57,
and 0.93 under basal, dDAVP, and AngII conditions, respec-
tively (Supplemental Figure 6).
Gene Ontology and Functional Annotation Analyses
Panthergeneontologytermmolecularfunctionanalysishighlighted
major processes highly enriched in mpkDCT and mpkCCD cells
(Supplemental Figure 7). The Database for Annotation, Visualiza-
tion and Integrated Discovery tool identified 11, 12, and 19 func-
tional processes in basal, dDAVP, and AngII conditions that were
highly enriched in at least one cell type (Figure 1F). For example,
mpkCCD cells. (C) Summary of abundance data from three in-
dependent experiments. Asterisks indicate significance relative to
control mpkCCD cells. ****P,0.001. (D) Representative AQP2
immunoblot from cells treated with cycloheximide (CHX) for vari-
ous time periods shows that the increased AQP2 levels in A4del-
CHIP cells are due to reduced AQP2 degradation. Samples are on
the same immunoblot with the same exposure time, and the break
is for illustration purposes only. (E) Summarized CHX data fitted
using nonlinear regression and a one-phase exponential decay
equation. AQP2 abundance is normalized to the zero time point.
Values are obtained from four independent experiments, with
n=3–6 for each individual time point.
Figure 3. CHIP interacts with AQP2 and modulates its abun-
dance. (A) Coimmunoprecipitation of AQP2, Hsc70, Hsp70, and 
CHIP from mpkCCD14 cells. “Load” indicates the relative ratio of 
sample loaded on immunoblots. Arrows indicate nonspecific Igs. 
IP, immunoprecipitation. (B) Representative immunoblot showing 
increased AQP2 levels in A4delCHIP cells relative to control
processes linked to PDZ domain proteins and N-linked glycosyla-
tionwere enriched inmpkDCT cells, whereas protein biosynthesis
was enriched in mpkCCD cells (Supplemental Table 5). Cluster
analysis of 250 proteins with the largest standard deviations under
three conditions showed six distinctive clusters (Supplemental Fig-
ure 8, Supplemental Table 6), indicating that dDAVPandAngII can
have similar—or independent—effects on a subset of proteins in
mpkDCTor mpkCCD cells.
Identification of DCT- and CCD-Selective Proteins
In Vivo
To confirm that our data could be translated to the in vivo
situation, we initially performed immunohistochemistry
(IHC) on mouse kidney tissue to localize selective proteins.
Double labeling with antibodies against NCC or AQP2 was
used to confirm localization to DCTor CCD cells, respectively.
As observed in mpkCCD cells, COP9 Signalosome Subunit 6
was highly expressed in CD cells in vivo, where it was localized
predominantly to the basolateral membrane of principal cells
(Figure 2A). Similarly, comparedwith theDCT, the E3 ubiquitin
ligase CHIP was highly expressed in the CD, where it partially
colocalized with AQP2 (Figure 2A, Supplemental Figure 9).
Matching the data from mpkDCT cells, the deubiquitylase
USP32 was only identified in DCT cells, where it localized
to both basolateral and apical membrane domains, with
some degree of colocalization with NCC. Similarly, F-Box
Protein 2 (FBXO2), was specific for DCT cells, where it
colocalized with NCC at the apical plasma membrane. A sim-
ilar distribution of FBXO2 (Supplemental Figure 10) and
CHIP (Supplemental Figure 11) was observed in human kid-
ney tissue. Because technical issues prevented analysis of the
majority of commercial antibodies using formaldehyde-fixed,
paraffin-embedded tissue or cryosections, we subjected puri-
fiedDCT cells isolated by FACS frommice with selective green
fluorescent protein expression in the DCT to Western blot-
ting. The mpkDCT-enriched proteins FBXO2, SMAD4, SIX4,
and FBXO29 were all abundant in isolated DCT cells (Figure
2B). In contrast, the mpkCCD-enriched proteins NRK1,
USP4, COP9 Signalosome Subunit 6, and CHIP were not
readily detected in isolated DCT cells.
Regulation of CHIP by AVP and Interaction of AQP2
and CHIP in mpkCCD Cells
The differential proteomics approach determined that the E3
ubiquitin ligase CHIP was highly enriched in cultured
mpkCCD cells. Immunoblotting of homogenates isolated
from different kidney zones (Supplemental Figure 12) con-
firmed the IHC results, namely that in vivo CHIP is expressed
throughout the kidney. CHIP abundance was significantly de-
creased after long-term dDAVP exposure in mpkCCD cells
(Supplemental Figure 13A) and mouse kidney (Supplemental
Figure 13B).
CHIP binds to the molecular chaperones Hsc70/Hsp7015
and can alter the turnover of bound clients. Because AQP2
interacts with Hsc70/Hsp7016,17 and CHIP is also expressed in
CD principal cells, we hypothesized that CHIP regulates
AQP2. In mpkCCD14 cell lysates, AQP2, CHIP, Hsc70, and
Hsp70 could be detected in samples coimmunoprecipitated
using an AQP2-specific antibody (Figure 3A). Similarly, we
could identify AQP2 in samples immunoprecipitated using
Hsc70 or Hsp70. Technical issues and antibody crossreactivity
prevented clear identification of AQP2 in samples immuno-
isolated from mpkCCD cells using a CHIP antibody.
Stable Knockdown of CHIP in mpkCCD Cells Alters
AQP2 Protein Abundance and t1/2
To examine the role of CHIP in regulation of AQP2, stable
knockdown of CHIP in mpkCCD cells using various shRNA
constructs was undertaken. Several independent cell popula-
tions (A1-A6delCHIP) showed significant reductions in CHIP
mRNA by quantitative RT-PCR relative to scrambled shRNA
control cells (Supplemental Figure 14A). Significant reduc-
tions in CHIP protein were detected in the A1-A6delCHIP
Figure 4. Inhibition of Hsp90 in control and delCHIP mpkCCD
cells support a role of CHIP in AQP2 degradation. (A) Repre-
sentative immunoblots from mpkCCD cells treated with the
Hsp90 inhibitor 17-AAG. (B) Summary of 17-AAG data from three
independent experiments. Asterisks indicate significance relative
to control conditions within an individual cell line. ***P,0.001;
****P,0.001; ####P,0.001 (significance between cell lines).
lines by Western blotting, which correlated with increased
AQP2 levels (Supplemental Figure 14B). One line (termed
A4delCHIP) was used for subsequent studies (Supplemental
Figure 14C). A consistent reduction in CHIP levels that cor-
responded with increased AQP2 levels was observed in total
protein homogenates fromA4delCHIP cells relative to control
mpkCCD cells at various cell passage numbers (Figure 3, B
and C). Cycloheximide studies (Figure 3D) showed that the
increased AQP2 abundance was, at least in part, due to signif-
icantly increased AQP2 protein stability and reduced degra-
dation, with the calculated AQP2 protein t1/2 in control
mpkCCD cells 1.8 hours (95% confidence interval, 1.59 to
1.97) compared with 2.7 hours (95% confidence interval,
2.24 to 2.88) in A4delCHIP cells (Figure 3E).
Inhibition of Hsp90 causes a shift from protein folding to
protein degradation via CHIP.18 Supporting a role for CHIP-
mediated AQP2 degradation, in control mpkCCD cells treated
with the Hsp90 inhibitor 17-N-allylamino-17-demethoxygel-
danamycin (17-AAG), Hsp70 levels were significantly in-
creased (a key biomarker for the inhibition of Hsp90), and
CHIP levels remained constant; however, AQP2 levels were
significantly decreased (Figure 4). Despite significantly in-
creased Hsp70 levels in 17-AAG–treated A4delCHIP cells,
AQP2 levels remained constant. Furthermore, AQP2 levels were
greatly reduced in control mpkCCD cells treated with the Hsp70
activator 2-[[3-Ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-
4-oxo-2-thiazolidinylidene]methyl]-1-methyl-pyridinium
chloride (Supplemental Figure 15), supporting a role of Hsp70
in modulating AQP2 expression.
To examine the degradation pathway of AQP2 and the role of
CHIP, the lysosomal inhibitor chloroquine and the proteasomal
inhibitor lactacystinwere used to inhibit the native degradation of
AQP2 that occurs in mpkCCD cells after dDAVP removal. In
control mpkCCD cells treated with chloroquine or lactacystin
(Figure 5, A and B), AQP2 levels were significantly reduced rela-
tive to nontreated cells. However, when control mpkCCD cells
were treated using chloroquine and lactacystin in combination,
AQP2 levels were not significantly altered (Figure 5, C and D). In
contrast, under similar conditions, chloroquine or lactacystin had
no significant effect on AQP2 levels in A4delCHIP cells (Figure 5,
in A4delCHIP cells. Samples are on the same immunoblot with the
same exposure time, and the break is for illustration purposes only.
(B) Summary of chloro and lacta data from three independent ex-
periments per treatment. (C) Representative AQP2 immunoblot
from cells treated with chloro, lacta, and chloro plus lacta com-
bined. AQP2 levels were not significantly altered when control
mpkCCD cells were treated using chloro and lacta in combination.
Chloro or lacta alone had no significant effect on AQP2 levels in
A4delCHIP cells. (D) Summary of chloro, lacta, and chloro plus lacta
combined data from three independent experiments per treat-
ment. Asterisks indicate significance relative to control conditions
within an individual cell line; hashtags indicate significance be-
tween cell lines. *0.01,P,0.05; **0.001,P,0.01; ***P,0.001;
#0.01,P,0.05; ##0.001,P,0.01.
Figure 5. CHIP plays a role in both lysosomal and proteasomal 
degradation of AQP2. (A) Representative AQP2 immunoblot from 
cells treated with the lysosomal inhibitor chloroquine (chloro) or 
the proteasomal inhibitor lactacystin (lacta) for 20 hours. In con 
mpkCCD cells, AQP2 degradation can occur in the presence of 
lysosomal or proteasomal inhibition, but this response is absent
C andD). These data indicate that AQP2 can be degraded by both
lysosomal or proteasomal pathways and that CHIP plays a role in
both processes.
Stable Knockdown of CHIP in mpkCCD Cells Alters
AQP2 Membrane Targeting and Ubiquitylation
AQP2 is ubiquitylated, whichmodulates its plasmamembrane
accumulation and lysosomal/proteasomal degradation.19,20 A
role for CHIP in these mechanisms was examined in A4del-
CHIP cells. Relative to control cells, apical plasma membrane
AQP2 levels in A4delCHIP cells were significantly greater after
dDAVP stimulation and remained higher 20 minutes after
dDAVP removal (Figure 6, A and B). Under identical conditions,
ubiquitylated AQP2 levels were significantly lower in untreated
A4delCHIP cells but returned to similar levels as control cells 30
minutes after dDAVP washout (Figure 6, C and D).
CHIP Modifies AQP2 In Vitro
CHIP has ubiquitin ligase activity.21–24 To assess whether CHIP
can directly ubiquitylate AQP2, we performed cellfree ubiquity-
lation assays. In the presence of ubiquitin, CHIP autoubiquityla-
tion and CHIP-mediated ubiquitylation of Hsc70 were readily
detectable (Figure 7).25 AQP2 readily forms stable oligomers
that are still present after protein reduction (Figure 7); however,
in the presence of CHIPand ubiquitin, AQP2wasmodified, result-
ing in highmolecular weight smearing typical of polyubiquitylated
proteins.Thishighmolecularweight shift didnotoccur in reactions
lacking CHIP or ubiquitin. Interestingly, modification of AQP2 is
Figure 6. Stable knockdown of CHIP in mpkCCD cells alters AQP2 membrane targeting and ubiquitylation. (A) Representative immunoblots of
apically biotinylated AQP2 in control or A4delCHIP cells under control, dDAVP (AVP), or dDAVP followed by 20 minutes washout (AVP washout)
conditions. Samples are on the same immunoblot with the same exposure time, and the break is for illustration purposes only. (B) Summary of
biotinylation data from five independent experiments. (C) Representative immunoblots of ubiquitylated AQP2 levels in control or A4delCHIP cells
under control, dDAVP (AVP), or dDAVP followed by 20minutes washout (AVP washout) conditions. Samples are on the same immunoblot with the
same exposure time, and the break is for illustration purposes only. Arrows represent nonspecific IgG bands. (D) Summary of ubiquitylation data
from three independent experiments. Asterisks indicate significance relative to control conditions within an individual cell line; hashtags indicate
significance for a specific condition between cell lines. *0.01,P,0.05; **0.001,P,0.01; ***P,0.001; #0.01,P,0.05; ##0.001,P,0.01.
attenuated in the presence ofHsc70, and the presence of AQP2
prevents both CHIP autoubiquitylation and CHIP-mediated
ubiquitylation of Hsc70, suggesting that CHIP can ubiquitinate
AQP2 in vitro; this interactionmay bemodified in the presence of
Hsc70, altering protein triage.
Increased AQP2 Levels in CHIP Gene–Modified Mice
CHIPwas undetectable in CHIP knockoutmice (CHIP2/2) (Fig-
ure 8A). AQP2 and pS256-AQP2 (a phosphorylation site impor-
tant for AQP2 trafficking26) levels in kidneys fromCHIP2/2mice
were significantly greater than those in controls (CHIP+/+) (Figure
8B). pS256-AQP2 levels were not increased in CHIP2/2 mice
when normalized to total AQP2 levels (Supplemental Figure
16). The increase in total AQP2 was qualitatively confirmed in
all regions of the kidney using IHC (Supplemental Figure 17).
Similarly, in kidneys from novel mice with a CHIP Thr247Met
mutation that results in loss of CHIP ubiquitin ligase activity
(CHIPM247/M247), AQP2 and pS256-AQP2 levels were signifi-
cantly greater than those in control mice (CHIPT247/T247) (Figure
9, A and B). In thismodel, CHIP levels are also significantly lower
(Figure 8, C and D), potentially reflecting the shorter t1/2 of the
mutated CHIP protein.27,28 Because of technical difficulties, im-
munoprecipitating AQP2 from mouse kidney, and detecting
ubiquitylated AQP2 with antiubiquitin antibodies, the levels of
ubiquitylated AQP2 in vivo in the two mouse
models could not be determined.
Altered Renal Water Handling in
CHIP2/2 and CHIPM247/M247 Mice
On 3 successive days, CHIP2/2 mice had
decreased fluid intake (Supplemental Fig-
ure 18A), with cumulative fluid intake
approximately 2.5-fold less than that of
controls (Figure 8, C and D). The osmolal-
ity of spontaneously voided urine from
CHIP2/2 mice was significantly higher on
each recorded day (Supplemental Figure
18B), with average urine osmolality in
CHIP2/2 mice 1.5-fold greater than that
of controls (Figure 8E). The higher urine
osmolality in CHIP2/2 mice relative to
controls correlated with significantly
greater urine sodium, potassium, chloride,
and urea concentrations (Table 1). How-
ever, when urinary electrolyte concentrations
were normalized to creatinine, no significant
differences were observed between the
genotypes (Table 1). The CHIPM247/M247
mice showed very similar baseline urine
electrolyte profiles to the CHIP2/2 mice
(Table 1), with cumulative fluid intake in
CHIPM247/M247 mice significantly lower
and urine osmolality significantly higher
than controls (Figure 9, Supplemental Figure
18, C and D). The baseline serum electrolyte
Figure 7. CHIP can ubiquitiylate AQP2 in vitro. Immunoblot analysis
of in vitro ubiquitylation reactions in the presence or absence of the
various recombinant proteins indicated, including ubiquitin (Ub). The
target of antibody used in the immunoblot (IB), molecular mass
markers (kilodaltons), and the presence of oligomeric AQP2 (AQP2n)
and polyubiquitylated AQP2 (AQP2Ub) are specified.
Figure 8. Increased AQP2 levels correlate with altered renal water handling in control 
(CHIP+/+) and CHIP knockout (CHIP2/2) mice. (A) Representative immunoblots of AQP2 and 
pS256-AQP2 in CHIP+/+ and CHIP2/2 mice kidneys. (B) Summary of data from CHIP+/+ and 
CHIP2/2 mice, with ten individual mice per genotype. (C) Cumulative data for water intake 
over a 3-day period. (D) Cumulative data for water intake relative to mouse body weight (BW) 
over a 3-day period. (E) Cumulative data for urine osmolality over a 3-day period. Asterisks 
indicate significance between genotypes. **0.001,P,0.01; ****P,0.001.
profiles of CHIP2/2, CHIPM247/M247, and
relevant control mice were unremarkable,
with no significant differences in any of the
measured parameters (Table 1).
Expression of Sodium Transporters
and AQPs
To examine whether the antidiuresis observed
in the CHIP gene–modified mice could be ex-
plained by alterations in other transport pro-
teins important for urinary concentration and/
or proteins regulated by the AVP signaling
pathway,29 we profiled the abundance of other
major sodium transporters and AQPs in kid-
neys from CHIP2/2, CHIPM247/M247, and rel-
evant control mice. No significant differences
in abundancebetween thegene-modifiedmice
and relevant controls were observed for any of
the examined proteins (Figure 10).
DISCUSSION
Epithelial cells of the DCTand CCD both seg-
regate and integrate the transport of water, sol-
utes, and ions to maintain systemic levels of
these substances and thus, body homeostasis.
Despite this critical role, very little was known
about which proteins play a regulatory role in
DCT and CCD cells and how these cell types
can be differentially regulated by similar phys-
iologic stimuli.Themajorgoalherewastousea
systemsbiology approach to identify novel and
uniqueregulatoryproteins important formod-
ulation of DCTand CCD function.
Figure 9. Increased AQP2 levels correlate with altered renal water handling in control
(CHIPT247/T247) and CHIP gene–modified (CHIPM247/M247) mice. (A) Representative
immunoblots of AQP2 and pS256-AQP2 in CHIPT247/T247 and CHIPM247/M247 mice
kidneys. (B) Summary of data from CHIPT247/T247 and CHIPM247/M247 mice, with six
individual mice per genotype. (C) Cumulative data for water intake over a 3-day pe-
riod. (D) Cumulative data for water intake relative to mouse body weight (BW) over a
3-day period. (E) Cumulative data for urine osmolality over a 3-day period. As-
terisks indicate significance between genotypes. *0.01,P,0.05; **0.001,P,0.01;
***P,0.001; ****P,0.001.
Table 1. Baseline urine and serum electrolyte profile of CHIP2/2and CHIPM247/M247 mice
Parameter CHIP+/+ CHIP2/2 P Value CHIPT247/T247 CHIPM247/M247 P Value
Plasma
Osmolality, mOsm/kg H2O 37468 37064 ns 37566 36963 ns
Na+, mmol/L 14760.5 14660.5 ns 14761 14560.5 ns
K+, mmol/L 4.9260.17 4.7660.39 ns 4.8560.26 4.6560.29 ns
Cl2, mmol/L 11461 11460.5 ns 11462 11361 ns
Urea, mmol/L 10.660.6 10.460.4 ns 8.660.3 8.060.5 ns
Urine
Na+, mmol/L 70611 9765 ,0.05 6767 9368 ,0.05
Na+-to-creatinine ratio 2462 2863 ns 2764 2763 ns
K+, mmol/L 94611 14168 ,0.01 11069 14569 ,0.05
K+-to-creatinine ratio 3464 3863 ns 3862 3962 ns
Cl2, mmol/L 145626 20265 ,0.05 154614 194617 ns
Cl2-to-creatinine ratio 5065 5564 ns 5666 5465 ns
Urea, mmol/L 990691 13496112 ,0.05 960660 1313679 ,0.01
Urea-to-creatinine ratio 354631 354618 ns 347624 351619 ns
Creatinine, mmol/L 2.860.2 3.860.3 ,0.01 2.960.3 3.860.3 ,0.05
Na+, Sodium; K+, Potassium; Cl2, Chloride.
ubiquitin ligaseCHIPwouldplaya role inmodulating the function
of AQP2. It is well established that, in the endoplasmic reticulum,
the chaperone proteins Hsp90 and Hsp70 play essential roles in
maintaining the balance between protein folding and ubiquitin-
dependent proteasomal degradation.31 If Hsp70-bound proteins
are bound to the cochaperone Hop, this facilitates their association
with the Hsp90 complex, promoting folding of the client protein.
However, Hsp70-bound proteins associating with CHIP are
targeted to endoplasmic reticulum–associated degradation
via the ubiquitin proteasome system.32–34 The association of
AQP2, CHIP, and Hsp70 in a protein complex plus the greater
abundance of AQP2 inmpkCCD cells with stable knockdown of
CHIP or in CHIP gene–modified mice suggest that AQP2 is
subject to similar quality control (QC) mechanisms. Therefore,
in the absence of CHIP, there is a shift in balance toward AQP2
protein folding rather than degradation. Support for the involve-
ment of this pathway for regulation of AQP2 includes the contin-
ued degradation of AQP2 in mpkCCD cells during lysosomal
inhibition (but not combined lysosomal/proteasomal inhibition),
the increased AQP2 protein t1/2 in CHIP-deficient cells, and the
fact that inhibition of Hsp90 in control but not CHIP-deficient
mpkCCD cells decreased AQP2 abundance.
Coimmunoprecipitation indicated that, in addition to
Hsp70, AQP2:CHIP may also form a complex with Hsc70.
AQP2:Hsc70 complexes have been identified,16,17 and the role of
this interaction has focused on AQP2 endocytosis. Because CHIP
plays a role inplasmamembraneQC(peripheralQC),35 itmay also
play a role inmodulating AQP2 endocytosis (Figure 11), similar to,
for example, unfolded CFTR.36 Such amechanism is supported by
(1) partial colocalization of CHIP and AQP2 in the apical plasma
membrane domain of CD principal cells, (2) reduced AQP2 ubiq-
uitylation in CHIP-deficient cells, (3) higher abundance of AQP2 in
the apical plasmamembrane in response to AVP in CHIP-deficient
cells, and (4) greater abundance of AQP2 in the plasmamembrane
of CHIP-deficient cells after AVP removal. However, one caveat to
this mechanism is that, in the presence of Hsc70, CHIP-mediated
polyubiquitylationofAQP2 in vitrowas reduced.This could indicate
that anHsc70:AQP2 complex limits CHIP-mediated ubiquitylation
or that peripheral QC of AQP2 involves an additional as yet un-
identified E3 ligase.35 A variety of other E3 ubiquitin ligases have
been identified inCDcells thatmay be important formodulation of
AQP2 function.37,38
The physiologic importance of CHIP for modulating AQP2 in
vivo was shown in two gene-modified mice models, which had
increased AQP2 levels, decreased fluid intake, and greater urine
osmolality relative to controls. The animals do not seem to have
“positive water balance,” because plasma electrolyte levels in
the two models are not significantly different from controls.
To some extent, the animals resemble a model of nephrogenic
syndrome of inappropriate antidiuresis39 but seem to compensate
by drinking less to maintain steady state and normal plasma os-
molality/electrolytes. On the basis of these data, pharmaceutical
inhibition ofCHIP could be a novel approach to treat certain forms
of nephrogenic diabetes insipidus and prevent the peripheral QC-
mediated internalization of misfolded AQP2 mutants that may
Figure 10. Abundances of other major sodium transporters and AQPs 
in kidneys from CHIP2/2, CHIPM247/M247, and relevant control mice. (A) 
Representative immunoblots of AQP3, AQP4, NKCC2, pNKCC2, 
NHE3, a-epithelial sodium channel (aENaC), gENaC, ROMK, and Na-
K-ATPase (a1-subunit) in CHIP+/+ and CHIP2/2 mice kidneys. Small 
arrows indicate nonspecific bands. (B) Summary of data from CHIP+/+ 
and CHIP2/2 mice, with ten individual mice per genotype. (C) Rep-
resentative immunoblots of AQP3, AQP4, NKCC2, pNKCC2, NHE3, 
aENaC, bENaC, ROMK, and Na-K-ATPase in CHIPT247/T247 and 
CHIPM247/M247 mice kidneys. (D) Summary of data from CHIPT247/T247 
and CHIPM247/M247 mice, with six individual mice per genotype.
mpkCCD and mpkDCT cells are excellent models of the 
CCD and DCT.2,4–6 Our SILAC-based large-scale quantitative 
LC-MS/MS30 allowed exceptional quantitative comparisons of 
their proteomes and has generated a large unbiased database 
that will provide a solid foundation for detailed targeted inves-
tigations into the roles of various proteins for regulating various 
homeostatic mechanisms unique to DCT and CCD cells.
Our proteomics data allowed us to generate and test the 
novel hypothesis that the CCD-enriched cochaperone and E3
reach the plasma membrane but are functional.40 Such an ap-
proach to control the peripheral QC therapeutically was proposed
for misfolded CFTR.41 Alternatively, activation of CHIP-mediated
protein QC should substantially reduce the enhanced levels of
AQP2 observed in various diseases with water retention (e.g., con-
gestive heart failure or liver cirrhosis).40
CONCISE METHODS
Extensive methods are included as Supplemental Material.
SILAC Labeling, High-pH Reversed Phase Fractionation,
Nanoliquid Chromatography and Mass Spectrometry,
Mass Spectrometry Data Analyses, and Bioinformatics
Extensive details are in Supplemental Material. The mass spectrom-
etry data have been deposited to the ProteomeXchange Consortium
via the PRIDE42 partner repository with the
dataset identifier PXD005454.
Isolation of Enhanced Green
Fluorescent Protein–Expressing
Mouse DCT Cells
All animal protocolswere performed in accordance
with licenses for the use of experimental animals
issued by the Danish Ministry of Justice. Extensive
details are in Supplemental Material. Enhanced
green fluorescent protein (EGFP) purity changed
from 4% before sorting to 94% after sorting in the
EGFP-positive sample and 0% in the EGFP-negative
sample.
Antibodies
For Western blotting, the antibodies used, the
supplier, and the predicted molecular weight of
the target protein are detailed in Supplemental
Table 7.
Fluorescent IHC and Confocal
Microscopy Analyses
Mouse kidney tissue was processed and labeled
as previously described.43
Generation of mpkCCD Cells with
Stable CHIP Knockdown
Generation of mpkCCD cells with stable CHIP
knockdown was performed as previously de-
scribed44 using MISSION lentiviral transduction
particles against CHIP (nos. 8527, 8528, 8530,
280520, and 280575) and corresponding control
particles (SHC002V) from Sigma-Aldrich.
Real-Time Quantitative PCR
Real-time quantitative PCR was performed as
previously described.44
mpkCCD14 Culture and Experimental Conditions for
CHIP Analyses
mpkCCD14 cells were cultured on semipermeable supports as pre-
viously described.45 For acute dDAVP stimulation, cells were washed
twice in pure media and reincubated in pure media for 3 hours before
being restimulated with dDAVP (1 nM) from the basolateral side for
20 minutes at 37°C. In dDAVP washout experiments, cells were subse-
quently washed twice in pure media and reincubated for 30 minutes at
37°C before sample preparation. For 17-AAG studies, indicated cells were
incubated with 2 mM 17-AAG for 16 hours before harvest. For Hsp70
activation studies, indicated cells were incubated with 5 mM 2-[[3-Ethyl-
5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]
methyl]-1-methyl-pyridinium chloride (Sigma-Aldrich) for 16 hours in
the presence of dDAVP before harvest. For proteasomal and lysosomal
inhibition experiments, after 72 hours of dDAVP treatment, cells were
washed twice in pure media and reincubated in pure media for 8 hours
Figure 11. Potential role of CHIP in AQP2 QC and trafficking. In the endoplasmic reticulum
(ER) under normal physiologic conditions, AQP2 polypeptide is bound by the chaperone
protein Hsp70. The cochaperone Hop facilitates the association with the Hsp90 complex,
promoting native folding of AQP2 that traffics to the Golgi apparatus, is organized into tet-
ramers, and stored in transport vesicles. As part of the ER QC, Hsp70-bound AQP2 that is
misfolded under normal conditions or after cellular stress associates with CHIP and is targeted
to endoplasmic reticulum–associated degradation (ERAD) via the ubiquitin proteasome
system. Other ERAD-associated E3 ligases are likely to be involved in ubiquitylation of AQP2.
Despite ER QC, a proportion of AQP2 escapes to the Golgi apparatus and is subsequently
stored in transport vesicles. Folded and misfolded AQP2 traffics to the plasma membrane
(PM) after AVP (VP) simulation. Because of peripheral QC, ER-misfolded AQP2 or AQP2
misfolded within the PM due to environmental stresses are recognized and bound by Hsc70.
Hsc70 associates with CHIP and other E3 ligases promoting AQP2 endocytosis and degra-
dation. Alternatively, internalized AQP2 may be deubiquitylated, refolded, and recycled to
the PM. In addition to QC-mediated endocytosis, regular AQP2 endocytosis may involve
Hsc70/CHIP. A number of the collecting duct–specific E3 ligases and deubiquitylases (DUBs)
identified may play important roles in these processes. Ub, ubiquitin.
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Immunoprecipitation Using mpkCCD14 Cells
Immunoprecipitation was performed as previously described.46
CHIP-Deficient Mice
Mice lacking CHIP expression (Stub1 targeted knockout, gene identifica-
tion 56424) B6;129-Stub1tm1Cpat/Mmnc (RRID:MMRRC_037422-UNC) 
on a mixed background of 129S/SvEv and C57BL/6 were previously re-
ported.47 For this line, knockout mice are delineated (CHIP2/2), and 
control animals are age- and sex-matched wild-type littermate controls 
(referred to as CHIP+/+).
Generation of CHIP (Stub1 Gene) T247M Mutant Mice
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and control animals are age- and sex-matched wild-type littermate con-
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Water Intake and Urine Collection in CHIP2/2 and CHIP 
M247/M247 Mice
All animal use was approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill under 
protocol 16–066. Extensive details are provided in Supplemental Material.
In Vitro Ubiquitylation Reactions
In vitro ubiquitylation reactions were performed as previously described.23
Statistical Analyses
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or the Tukey multiple comparison test, respectively. Significance was con-
sidered at P,0.05.
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Supplemental Table 7. Detailed information on Antibodies
Antibody Supplier Cat. No. or Reference Predicted MW (kDa) 
Ubiquitin Cell Signaling 3936 N/A 
PSMD14 Cell Signaling 4197 35 
USP14 Cell Signaling 11931 60 
USP4 Cell Signaling 2651 110 
OTUB1 Abcam ab82154 31 
RNF128 Abcam ab72533 45-70
CHIP (Stub1) Abcam ab134064 35 
Proteasome 
20S 
Abcam ab3325 30 
AQP3 Abcam ab153694 25 and 32-40 
CSN6 Santa Cruz sc47965 34 
USP5 Santa Cruz sc366624 96 
USP7 Santa Cruz sc30164 135 
USP32 Santa Cruz sc374465 130-190
USP47 Santa Cruz sc100633 157 
FBXO2 Santa Cruz sc393873 42 
FBXO29 Santa Cruz sc514385 60-70
Ure-b1 Santa Cruz sc49768 400 
Six4 Santa Cruz sc55766 80 
Smad4 Santa Cruz sc7966 60 
Nek9 Santa Cruz sc50765 120 
NRK1 Santa Cruz sc398852 25 
HSP70 Enzo ADI-SPA-810 70 
Hsc70 Enzo ADI-SPA-815 71 
ROMK Novus NBP1-82874 45 
CHIP (Stub1) Novus NBP2-47510 35 
AQP4 Alamone AQP-004 30 
Actin Sigma-Aldrich A2228 42 
AQP2 9398 N/A Moeller HB, Aroankins TS, Slengerik-Hansen  J, Pisitkun T, Fenton RA: Phosphorylation and ubiquitylation are opposing 
processes that regulate endocytosis of the water channel aquaporin-2. J Cell Sci 127: 3174-3183, 2014 
25 and 35-45 
pS256-AQP2 N/A Hoffert JD, Fenton RA, Moeller HB, Simons B, Tchapyjnikov D, McDill BW, Yu MJ, Pisitkun T, Chen F, Knepper MA: 
Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. J Biol 
Chem 283: 24617-24627, 2008 
25 and 35-45 
NKCC2 N/A Ecelbarger CA, Terris J, Hoyer JR, Nielsen S, Wade JB, Knepper MA. Localization and regulation of the rat renal Na(+)-K(+)-
2Cl- cotransporter, BSC-1. Am J Physiol 271: F619–F628, 1996 
140 
pNKCC2 N/A Dimke H, et al. Acute growth hormone administration induces antidiuretic and antinatriuretic effects and increases 
phosphorylation of NKCC2. Am J Physiol Renal Physiol  292: F723–F735, 2007 
140 
NHE3 N/A Kim GH, Ecelbarger C, Knepper MA, Packer RK. Regulation of thick ascending limb ion transporter abundance in response to 




N/A Kashgarian, M., Biemesderfer, D., Caplan, M., and Forbush, B. 3rd.. Monoclonal antibody to Na,K-ATPase: 
immunocytochemical localization along nephron segments. Kidney Int 28: 899–913, 1985 
90 
Alpha-ENaC N/A Sorensen MV, et al. Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in 
mice. Kidney Int 83: 811–824, 2013 
90 and 25 (cleaved) 
Gamma-ENaC N/A Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma 
subunit proteins in rat kidney. J Clin Invest  104:R19–R23, 1999 
85 
Supplemental Figure 1. Proteomics experimental workflow. mpkDCT cells were cultured in heavy SILAC 
medium (Lys+6, Arg+10) while mpkCCD cells in light SILAC medium (Lys+0, Arg+0). Four passages of 
labelled cells were used to generate four biological replicates for statistical analysis. In addition to control 
conditions, cells were also stimulated for 4 days with the vasopressin type II receptor agonist 1-desamino-8-D-
arginine vasopressin (dDAVP, 1nM, only to basolateral (baso) side) or angiotensin-2 (ANGII, 1nM, to both 
apical and basolateral sides). Cells were harvested, equally pooled and subjected to offline high-pH 
fractionation based two dimensional LC-MS/MS analysis (Q-Exactive). 
Supplemental Figure 2. Loading controls for immunoblotting of mpkDCT and mpkCCD cells. Equal 
protein equivalents of samples isolated from the different cell types and different treatments were used for 
subsequent immunoblotting as demonstrated by Coomassie gel (A) or immunoblot of actin (B). 
Supplemental Figure 3. Immunoblotting for a variety of the regulatory proteins identified in mpkDCT or 
mpkCCD cells. Specificity of the commercial antibodies was based on that they either gave a single unique 
band on an immunoblot corresponding to the target proteins predicted molecular weight, or the most prominent 
band on the immunoblot was at the target proteins predicted molecular weight (with no other bands of similar 
size). 
 Supplemental Figure 4. Immunoblot quantification of selected DUB genes in mpkDCT and mpkCCD 
cells grown under three conditions. The mpkDCT control condition was set as baseline, and all other 
quantifications were relative to mpkDCT control condition. * denotes significance between DCT and CCD 
under the same condition (DCT used as reference) while # denotes significance within one cell type under 
different conditions (control condition used as reference). *or #: 0.01<p<0.05; ** or ##: 0.001<p<0.01; *** or 
###: 0.0001<p<0.001; **** or ####: p<0.0001. 
Supplemental Figure 5. Immunoblot quantification of selected kinase, E3 ligase and TF genes in 
mpkDCT and mpkCCD cells grown under three conditions. The mpkDCT control condition was set as 
baseline, and all other quantifications were relative to mpkDCT control condition. * denotes significance 
between DCT and CCD under the same condition (DCT used as reference) while # denotes significance within 
one cell type under different conditions (control condition used as reference). *or #: 0.01<p<0.05; ** or ##: 
0.001<p<0.01; *** or ###: 0.0001<p<0.001; **** or ####: p<0.0001. 
Supplemental Figure 6. The correlation between immunoblot based quantification and mass 
spectrometry based quantification for selected genes in mpkDCT and mpkCCD cells grown under three 
conditions. (A) Control condition; (B) dDAVP treatment; (C) AngII treatment. The spearman’s correlation 
coefficient was calculated for each condition. 
Supplemental Figure 7. GO-term molecular function analysis by Panther. (A) Control condition; (B) 
dDAVP treatment; (C) AngII treatment. Cell specific genes under each condition were used as Panther inputs. 
Supplemental Figure 8. Cluster analysis of 250 proteins with the largest standard deviations under 
three conditions showed 6 distinctive clusters. The data indicates that dDAVP and AngII can have similar – 
or independent – effects on a subset of proteins in mpkDCT or mpkCCD cells. For example, the abundance of 
proteins in Clusters 2 and 4 are specifically regulated by dDAVP (but not by AngII), the abundance of proteins 
in Clusters 3 and 5 are specifically regulated by AngII (but not by dDAVP), whereas the abundance of proteins 
in Clusters 1 and 6 can be regulated by both dDAVP or AngII. 
Supplemental Figure 9. Immunohistochemical localization of CHIP in mouse kidney. Confocal images of 
CHIP and AQP2 distribution in mouse kidney cortex, outer medulla and medulla. CHIP is expressed in 
principal cells throughout the collecting duct system where it partially colocalizes with AQP2.  
Supplemental Figure 10. Immunohistochemical localization of FBXO2 in human kidney. Confocal 
images of FBXO2 distribution in human kidney cortex. Differential interference contrast (DIC) images are 
provided to demonstrate the structure of the imaged section. FBXO2 is localized to tubules morphologically 
resembling the DCT. 
Supplemental Figure 11. Immunohistochemical localization of CHIP in human kidney. Confocal images 
of CHIP and AQP2 distribution in human kidney cortex and medulla. CHIP is expressed in collecting duct 
principal cells where it partially colocalizes with AQP2.  
Supplemental Figure 12. CHIP distribution in different mouse kidney zones. Immunoblotting of total 
protein homogenates isolated from mouse kidney cortex, outer medulla and inner medulla demonstrate that 
CHIP is abundantly expressed in all regions examined. AQP2 is more abundant in the outer medulla and inner 
medulla. Immunoblotting for actin serves as a loading control. 
Supplemental Figure 13. In vitro and in vivo effects of dDAVP on CHIP and AQP2 abundance. A) 
Representative immunoblots of AQP2 and CHIP following dDAVP treatment of mpkCCD cells. B) Semi-
quantitative summary of data. * indicates significance relative to 0 h time point. C) Representative immunoblots 
of AQP2 and CHIP in mice kidneys following dDAVP treatment of mice. Each lane represents an individual 
mouse sample. D) Semi-quantitative summary of data. * indicates significance relative to time-matched control 
group. *: 0.01<p<0.05; **: 0.001<p<0.01; ***: 0.0001<p<0.001; ****: p<0.0001. 
Supplemental Figure 14. Initial characterization of CHIP knockdown mpkCCD cells. A) RT-qPCR 
detection of CHIP mRNA levels in various lentivirus transduced CHIP shRNA expressing mpkCCD cells (A1-
A6 delCHIP). Significant reductions in CHIP mRNA levels are observed in all the individual delCHIP lines 
relative to wildtype (WT) mpkCCD cells or scrambled shRNA control cells. B) Immunoblotting of CHIP 
demonstrates a clear reduction of CHIP protein in the A1-A6 delCHIP lines relative to wildtype (WT) mpkCCD 
cells or scrambled shRNA control cells. In each line the decrease in CHIP correlates with increased levels of 
AQP2. C) The A4delCHIP cells were used for the remainder of studies and showed a consistent reduction in 
CHIP protein levels relative to WT or scrambled shRNA expressing Con mpkCCD cells.  
Supplemental Figure 15. Treatment of control mpkCCD cells with the Hsp70 activator YM-1 
significantly reduces AQP2 levels. A) Immunoblotting of AQP2, Hsp70 and actin in samples isolated from 
cells treated with YM-1, which activates Hsp70 in a similar manner to Hip and stabilizes Hsp70 in its ADP-
bound conformation favoring degradation of misfolded substrates. AQP2 levels are substantially reduced, 
strengthening the role of an Hsp70/CHIP dependent AQP2 degradation mechanism. Hsp70 levels are not 
affected by YM-1 treatment. Actin serves as a loading control. B) Quantification of AQP2 and Hsp70 in control 
and YM-1 treated mpkCCD cells. Values are obtained from 3 independent experiments with n = 3–4 for each 
individual treatment. * denotes significance between control and YM-1 treated cells. ****: p<0.0001. 
Supplemental Figure 16. pS256-AQP2 levels are not significantly greater in CHIP-/- and CHIP M247/M247 
mice when total AQP2 levels are considered. Summary of data from CHIP+/+ mice and CHIP-/- mice 
(n=10/genotype) demonstrating that when normalized to total AQP2 the levels of pS256-AQP2 are not different 
between the genotypes. Similar results are observed for the CHIPM247/M247 and CHIPT247/T247 mice 
(n=6/genotype). 
Supplemental Figure 17. Immunolabelling of AQP2 in kidneys from CHIP+/+ and CHIP-/- mice. Images are representative confocal 
images of AQP2 expression in kidney sections from the kidney cortex, outer medulla and inner medulla of CHIP+/+ and CHIP-/- mice. 
AQP2 levels were increased throughout the collecting duct in CHIP-/- mice, with apical labeling being more apparent. Differential 
interference contrast (DIC) images are provided to demonstrate the structure of the imaged section. A Leica TCS SL confocal 
microscope with an HCX PL APO 63× oil objective lens (numerical aperture: 1.40) was used with identical microscope settings (PMT 
offset and gain, sampling period, and averaging) for obtaining images. The dynamic range of the image acquisition was set so that the 
sections with the most intense fluorescence signal only had a few saturated pixels. 
Supplemental Figure 18. Baseline renal water handling of CHIP-/- and CHIPM247/M247 mice. A) CHIP-/- mice 
had decreased fluid intake on three successive days. B) The osmolality of spontaneously voided urine from 
CHIP-/- mice was significantly higher on each recorded day. C) CHIPM247/M247 mice had decreased fluid intake 
on three successive days. D) The osmolality of spontaneously voided urine from CHIPM247/M247 mice was 
significantly higher on the last two recorded days. * denotes significance between CHIP+/+ and CHIP-/- or 
CHIPT247M/T247M mice. *: 0.01<p<0.05; **: 0.001<p<0.01; ***: 0.0001<p<0.001. 
Supplemental Detailed Methods 
Cell culture and SILAC labeling. mpkDCT and mpkCCD cells were grown at 37oC/5%CO2 in 
SILAC advanced DMEM/F12-Flex media (Invitrogen) containing 60 nM sodium selenite, 5 μg/ml 
transferrin, 2 mM glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 10 ng/ml epidermal 
growth factor, 5 μg/ml insulin, 20 mM D-glucose and 20 mM HEPES (pH 7.4) in light (mpkCCD; 
contains 12C6 lysine, 12C6 14N4 arginine, for mpkCCD) or heavy (mpkDCT; contains 13C6 lysine, 
13C6 15N4 arginine, for mpkDCT) conditions for at least 5 passages to allow >97% labeling 
efficiency as confirmed by MS analysis. For experiments, cells were grown on semi-permeable 
supports (Transwell, Corning) until polarized monolayers were formed (transepithelial resistance 
(TER) >5 kΩ.cm2). Cells were subsequently cultured in serum-free media (media changed every 
12 h) in the following groups; 1) Control, 2) 1 nM [deamino-Cys1,D-Arg8]vasopressin (dDAVP) 
(10−9 M, Sigma) to only the basolateral side; 3) 1nM AngII (Sigma). After 4 days, cells were 
washed twice in ice-cold PBS and scraped in cell lysis buffer (8 M urea, 2 M thiourea, 50 mM 
Tris, pH 7.5) containing protease and phosphatase inhibitors (Halt protease and phosphatase 
inhibitors, Pierce). After 20 min incubation, lysates were sonicated on ice and centrifuged at 
16,000g for 10 min at 4oC. Supernatant protein concentration was measured by Bradford assay 
(Biorad), and equal protein amounts from mpkDCT and mpkCCD samples within each treatment 
group were pooled together. Per condition, four independent passages of cells were compared. 
Pooled samples were reduced, alkylated, and digested with trypsin and subjected to further 
high-pH reversed phase fractionation 1.  
High-pH reversed phase fractionation. Peptides were loaded onto a ZORBAX Extend-C18 
reversed phase column (Agilent, 3.5µm particle size, 4.6 x 150mm) and fractionated using 
Ultimate 3000 Liquid Chromatography (LC) (Dionex). Buffer A was 25mM NH4FA in 100% H2O 
(pH adjusted to 9.5 with NH3·H2O) and buffer B was 25mM NH4FA in 10% H2O/90%ACN (equal 
volume of NH3·H2O added as in buffer A). The fractionation was done by a linear gradient of 2-
35% buffer B for 56 min plus a linear gradient of 35-80% buffer B for 8 min. One fraction was 
collected every 2 minutes, so there were 32 fractions in total. These 32 initial fractions were 
then combined into 8 final fractions through combining 4 fractions with the same time interval 
into one e.g. fractions 1, 9, 17 and 25 were pooled into final fraction 1. The final fractions were 
vacuum-dried and stored in -20°C until MS analysis.  
Nano-liquid chromatography and mass spectrometry (nLC-MS) analysis. Fractionated 
peptides were analyzed by nano Liquid-Chromatography (nLC) (Easy LC 1000, Thermo 
Scientific) coupled to a Q-Exactive mass spectrometer (Thermo Scientific) through an EASY-
Spray nano-electrospray ion source (Thermo Scientific). A pre-column (Acclaim®PepMap 100, 
75 µm x 2 cm, C18, 3 µm, 100 Å, Thermo Scientific) was used to trap peptides and an analytical 
column (EASY-Spray Column, PepMap, 75 µm x 15 cm, C18, 3 µm, 100 Å, Thermo Scientific) 
was used to separate peptides. Buffer A was 100%H2O/0.1% FA and buffer B was 100% 
ACN/0.1% FA. A 36-minutes linear gradient from 5% to 35% buffer B was used to separate 
peptides. MS settings were as follows: full scans (m/z 300-1800) were performed at a resolution 
of 70,000 with an automatic gain control (AGC) threshold of 3e6, a maximum injection time (IT) 
of 100ms, and 12 data dependent MS/MS scans at a resolution of 17,500 with AGC of 1e5 and 
IT of 50ms. HCD collision energy was 28%. Dynamic exclusion was set at 30 s, and precursor 
ions with charge state unknown, +1 and above +8 were excluded for fragmentation. 
MS data analysis. Identification and quantification were done by MaxQuant (version 1.5.2.8). 
Raw files from each biological replicate under each treatment condition were searched together 
to generate a combined result. Data were searched against RefSeq mouse database (58513 
sequences, downloaded Oct. 2014) plus normal contaminants. Multiplicity was set to 2, with 
Arg10 and Lys6 as heavy labels. Acetylation of Protein N-term, oxidation of methionine, and 
phosphorylation of serine, threonine and tyrosine were set as variable modifications, and they 
were also included in protein quantification. iBAQ calculation was turned on. All other 
parameters, including precursor and fragment mass tolerances, were set as default values of 
MaxQuant. Proteins that were identified and quantified in at least three biological replicates 
were regarded as quantifiable proteins and subjected to Benjamini-Hochberg (BH) FDR 
estimations, and up-regulated proteins in one cell type (mpkDCT or mpkCCD) that passed 1% 
BH-FDR threshold were regarded as enriched proteins in that cell type. Proteins that had valid 
iBAQ values in one labeling channel (heavy or light) in at least three biological replicates and 
“zero” iBAQ values in the other channel in all replicates were regarded as unique proteins in 
either mpkDCT (heavy channel) or mpkCCD (light channel). The enriched plus unique proteins 
for each cell type (mpkDCT or mpkCCD) were defined as “specific” proteins for that cell type 
and retained for further analysis. 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis. 
mpkDCT and mpkCCD specific proteins were subjected to DAVID (v6.7) functional annotation 
analysis. mpkDCT and mpkCCD specific protein accessions were transformed to gene symbols 
using Automated Bioinformatics Extractor (ABE) 2 and used as separate inputs. A customized 
background, containing all the protein accessions identified in this study, was used instead of 
the default Mus musculus background. In order for the DAVID to recognize as many 
background accessions as possible, the original RefSeq protein accessions were transformed to 
UniProt accessions using the ID Mapping tool from UniProt (http://www.uniprot.org/uploadlists/). 
Functional annotation clustering with default settings was performed separately on mpkDCT and 
mpkCCD specific proteins against the customized background. Annotation clusters between 
mpkDCT and mpkCCD that share 50% or above individual annotations were mapped together 
and deemed identical, and a cluster name was given for each mapped cluster. Mapped clusters 
that had enrichment p-values no greater than 0.1 (corresponding to enrichment score no smaller 
than 1) in either mpkDCT or mpkCCD were retained to generate a heatmap, to illustrate which 
functions are more enriched in one cell type compared to the other. 
Isolation of Enhanced Green Fluorescent Protein (EGFP) expressing mouse DCT cells. All 
animal protocols were performed in accordance to licenses for the use of experimental animals 
issued by the Danish Ministry of Justice. Mice had free access to standard rodent chow and 
water. Transgenic mice expressing EGFP driven by the parvalbumin promoter 3 were 
euthanized by cervical dislocation and kidneys quickly removed. The kidneys were sliced into 
approximately 1 mm pieces and incubated for 40 min in buffer B (125 mM NaCl, 0.4 mM 
KH2PO4, 1.6 mM K2HPO4, 1 mM MgSO4, 10 mM Na-acetate, 1 mM α-ketogluterate, 1.3 mM 
Ca-gluconate, 5 mM glycine, 30 mM glucose and 5 μg/mL DNase I (Sigma), pH 7.4) containing 
2 mg/ml collagenase B (Roche). Samples were mixed continuously at 850 rpm at 37°C. After 10 
min, half of the enzyme solution was removed and replaced with buffer B without collagenase, 
and samples were incubated for a further 10 min. This procedure was repeated for another 10 
min. After a total incubation of 40 min, the tubular suspensions were passed through a 100 µM 
cell strainer (BD Falcon), and centrifuged for 3 min at 200 g. Cells were washed with a 
trypsin/EDTA solution (Lonza) containing 10 mM HEPES, 30 mM glucose and 50 ug/ml DNase I. 
Cells were again resuspended in trypsin/EDTA solution and incubated for 15 min at 37°C. Cells 
were washed in DMEM/HamF12 cell culture medium (Gibco) containing 5% FBS, 30 mM 
glucose, 10 mM HEPES and 50 mg/ml DNase I and subsequently resuspended in 1.5 ml 
medium. Cells were passed through a 40 µM cell strainer and kept at 4⁰C. EGFP-positive and 
negative cells were isolated on a FACSAria III (BD Biosciences) machine at the FACS Core 
Facility, Aarhus University, Denmark. Sorted cells were centrifuged for 10 min at 3,000 g at 4⁰C 
and the pellet was resuspended in 1x Laemmli sample buffer (62.5 mM Tris, 8.75% Glycerol, 3% 
SDS, 89.5 µM Bromphenolblue, 15 mg/ml DTT, pH 6.8). Samples were heated for 10 min at 
65⁰C. EGFP purity changed from 4% before sorting to 94% after sorting in the EGFP-positive 
sample and 0% in the EGFP negative sample.  
Antibodies. For western blotting, the antibodies utilized, the supplier and the predicted 
molecular weight of the target protein are detailed in Supplemental Table 7. Specificity of the 
commercial antibodies was based on that they either gave a single unique band on an 
immunoblot corresponding to the target proteins predicted molecular weight, or the most 
prominent band on the immunoblot was at the target proteins predicted molecular weight (with 
no other bands of similar size). Other characterized antibodies were AQP2 9398 4 and pS256-
AQP2 5. 
Fluorescent immunohistochemistry and confocal microscopy analysis. Specimens of 
human tissue were obtained post-mortem from the pathology archives at Aarhus University 
Hospital 
(http://www.en.auh.dk/departments/cancer+and+inflammation+centre/department+of+histopath
ology/research). Studies on this tissue were performed after approval from the local ethical 
committee, Aarhus County, Denmark. Archived paraffin-embedded mouse kidney tissue was 
processed as previously described 6. Tissue from the CHIP gene-manipulated mice was 
immersion fixed in 4% PFA in PBS for 24 h before being processed as previously described 6. 
Sections were immunolabeled for confocal laser scanning microscopy as previously described 6 
using CSN6 (sc47965), USP32 (sc374465), CHIP (sc133066), FBXO2 (sc393873), AQP2 C17 
(sc9882) and NCC (SPC402D, Stressmarq). A Leica TCS SL confocal microscope with an HCX 
PL APO 63 x oil objective lens (numerical aperture: 1.40) was used for imaging of labelled 
sections (Leica Microsystems). For qualitative assessment of AQP2 abundance, microscope 
settings (PMT offset and gain, sampling period, and averaging) were equal for obtaining images. 
The dynamic range of the image acquisition was set so that the sections with the most intense 
fluorescence signal only had a few saturated pixels. Brightness was digitally enhanced on 
presented images. 
Generation of mpkCCD cells with stable CHIP knockdown. MISSION lentiviral transduction 
particles against CHIP (numbers 8527, 8528, 8530, 280520, 280575) and corresponding control 
particles (SHC002V) were from Sigma. mpkCCD14 cells were cultured as described7 in 24-well 
plates until 95% confluent. Cells were treated with hexadimethrine bromide (8 μg/ml final 
concentration) for 15 min in pure media, before addition of lentiviral particles (multiplicity of 
infection = 1.5). Transduction was allowed to proceed for 24 h, after which media was switched 
to mpkCCD14 media containing 2 μg/ml of puromycin for selection. Multiple clonal cell lines 
were isolated and individually characterized by examination of cell morphology, high TEER 
when grown on semi-permeable supports, CHIP expression levels by western blotting and RT-
qPCR. 
Real time quantitative PCR (RT-qPCR). Total RNA was isolated using the Ambion Ribopure 
kit (Invitrogen), treated with DNase I (Invitrogen), and reverse transcribed using Superscript II 
and random primers (Invitrogen); all steps were performed according to the manufacturer's 
instructions. A control reaction without the reverse transcriptase enzyme was performed to 
exclude genomic DNA amplification. Primer pairs utilized spanning an exon-exon junction or an 
intron were: AQP2 (5′-TGGCTGTCAATGCTCTCCAC and 5′-GGAGCAGCCGGTGAAATAGA); 
STUB (5’-TCTACCCTCAATTCCGCCTT and 5’-GTGGCAGCGGTCATTGAGAA); 18S RNA (5′-
GGATCCATTGGAGGGCAAGT and 5′-ACGAGCTTTTTAACTGCAGCAA). Specificity of the 
amplified products was determined using melting curve-analysis software, gel electrophoresis, 
and sequencing. Amplification was performed using the cDNA equivalent of 5 ng of RNA, 5 
pmol of each primer and either HotStar Taq polymerase (Qiagen) or SYBR Green I Master Taq 
(Roche Applied Science). Cycling conditions were: 95 °C for 5 min, followed by 40 cycles of 
95 °C for 10 s, 60 °C for 20 s, and 72 °C for 30s. RT-qPCR reactions were run on a LightCycler 
480 (Roche), with fluorescence measured at the end of each elongation step to calculate Ct 
values. Relative quantitation of gene expression was determined using the comparative Ct 
method. Signals for ribosomal 18S RNA amplified in parallel were used to normalize for 
differences in the amount of starting cDNA. 
mpkCCD14 culture and experimental conditions for CHIP analysis. mpkCCD14 cells were 
cultured on semi-permeable supports (0.4 μM pore size, Corning) until a confluent monolayer 
formed and TER was above 5 kOhm/cm2. 1 nM dDAVP was added in serum-free media to the 
basolateral compartment for 72 h to induce AQP2 expression. For acute dDAVP stimulation, 
cells were washed twice in pure media and reincubated in pure media for 3 h before re-
stimulated with dDAVP (1 nM) from the basolateral side for 20 min at 37 °C. In dDAVP washout 
experiments, cells were subsequently washed twice in pure media and reincubated for 30 min at 
37 °C before sample preparation. For 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) 
studies, where indicated cells were incubated with 2µM 17-AAG for 16h before harvest. For 
Hsp70 activation studies, where indicated cells were incubated with 5 µM 2-[[3-Ethyl-5-(3-
methyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]methyl]-1-methyl-pyridinium 
chloride (YM-1, Sigma) for 16h in the presence of dDAVP before harvest. For proteasomal and 
lysosomal inhibition experiments, after 72 h of dDAVP treatment, cells were washed twice in 
pure media and re-incubated in pure media for 8 h in the presence of 10 µM lactacystin, 150µM 
chloroquine or both, as indicated. For studies examining the long-term effects of ddAVP, cells 
were incubated with 1 nM dDAVP from the basolateral side for indicate time points. For 
cycloheximide chase studies, cells were incubated for various time points at 37 °C and 5% CO2 
in 50 μM cycloheximide. Cells were washed twice in PBS and proteins were extracted in 
Laemmli sample buffer containing 10 mg/ml of DTT. For calculation of the protein half-life, 
average band densities for each time point were normalized to control and fitted using nonlinear 
regression and a one-phase exponential decay equation using GraphPad Prism software. Data 
were obtained from four independent experiments, with 3–6 observations for each individual 
time point.  
Effects of dDAVP in mice. All animal work has been conducted according to relevant national 
and international guidelines. Animal housing conditions and experiments were approved by the 
Danish Ministry of Justice. Care of animals was in accordance with institutional guidelines. Mice 
were housed individually in metabolic cages and received 1 ng/h dDAVP via osmotic minipump 
for the indicated timeframes. Control animals received saline vehicle. At the end of the 
experiment, mice were euthanized by cervical dislocation and the kidneys processed as 
previously described 8.   
Surface biotinylation of mpkCCD14 cells. Apical plasma membrane proteins were labeled 
with EZ-link hydrazide-biocytin (Pierce) as previously described 9.  
Immunoblotting. Standard procedures were utilized for sample preparation and SDS-PAGE. 
Immunoblots were developed using ECL detection and signal intensity in specific bands were 
quantified using Image Studio Lite (Qiagen) densitometry analysis. 
Immunoprecipitation (IP) using mpkCCD14 cells. IP was performed as previously described4. 
Mouse models of CHIP dysfunction. All animal use was approved by the Institutional Animal 
Care and Use Committee at the University of North Carolina at Chapel Hill. Mice lacking CHIP 
expression (Stub1 targeted knockout, gene ID: 56424) B6;129-Stub1tm1Cpat/Mmnc 
(RRID:MMRRC_037422-UNC) on a mixed background of 129S/SvEv and C57BL/6 were 
previously reported 10. For this line, knockout mice are delineated (CHIP-/-) and control animals 
are age and sex matched wildtype littermate controls (referred to as CHIP+/+). 
Generation of CHIP (Stub1 gene) T247M mutant mice. Guide RNA Cloning: Guide RNA 
protospacer (target) sequences were cloned into a T7 promoter vector in context with guide 
RNA structural elements, allowing T7-mediated in vitro transcription to produce the full guide 
RNA molecule. A guanine was added to the 5’ end of protospacer sequences that do not have a 
native 5’ guanine to allow T7 in vitro transcription initiation. T7 ligation mixtures were 
transformed into Stellar competent cells. Miniprep DNA was sequence-verified. Guide RNA In 
Vitro Transcription. Guide RNA plasmids were linearized with DraI, purified by silica column 
(Qiaquick) and used as template for T7 in vitro transcription using the NEB HiScribe T7 kit. 
Reactions were performed at 37°C overnight as recommended by the manufacturer using 1000 
ng linear guide RNA plasmid. After addition of DNAse I for 30 min, guide RNAs were purified 
using Qiagen RNEasy mini kit, eluted in 30 μl RNAse-free microinjection buffer (5 mM Tris-Cl 
pH7.5, 0.1 mM EDTA) and quantitated on a Nanodrop spectrophotometer. Guide RNA Activity 
Test: The Cas9/guide RNA target region was PCR amplified from wild-type C57BL/6 DNA using 
primers Stub1-ScF1 (5’-GGAGACAGGAGTTGCCCACACA-3’) and Stub1-ScR1 (5’- 
CAGTTCAGAACCCATCAGCAGG-3’). PCR product was purified on a silica minicolumn and 
eluted in 10 mM Tris-Cl pH8.5. In Vitro Cleavage Assay: Guide RNAs were tested for activity in 
1x NEB restriction buffer 3, 1 mg/ml BSA, 30 μg/ml Cas9 protein, 300 ng target DNA and 600 ng 
guide RNA in a 20 μl reaction volume. A control reaction was performed in parallel with all 
components except guide RNA. Reactions were incubated at 37°C for 1 hr followed by 80°C for 
10 min, separated on 2% Agarose TAE gels and imaged using a standard ethidium bromide gel 
imaging system. Guide RNA Stub1-g82T (GAACCCTGCATTACACCCAGTGG, protospacer 
associated motif NGG underlined) produced nearly 100% target site cleavage. Mouse 
production: Genome editing was performed using CRISPR/Cas9 technology with the 
modification of mouse sequence NM_019719 at ntds #740 and #741 resulting in change of 
Threonine247 to Methionine (ACA to ATG). Founder animals were produced by microinjection 
of C57BL/6J embryos with a mixture of 100 ng/ul Cas9 mRNA, 50 ng/ul Stub1 guide RNA g82T 
and 100 ng/ul donor oligonucleotide Stub1-T247M-T (5’- 
TGACTACTTGTGTGGCAAGATTAGCTTTGAGCTGATGCGGGAACCCTGCATTATGCC 
CAGTGGTATCACCTATGACCGCAAGGACATTGAGGAGCACCTGCAGGTAAG-3’) in 5 mM 
Tris pH7.5, 0.1 mM EDTA. Injected embryos were surgically implanted in CD-1 pseudopregnant 
recipients and resulting pups were genotyped by PCR amplification of the Stub1 T246 region 
followed by Sanger sequencing. Animals harboring the Stub1 T246M codon change were 
identified by deconvolution of sequence traces. Founder animals were mated to wild-type 
C57BL/6J animals and F1 animals harboring the T246M mutation were intercrossed to generate 
homozygous animals ((Stub1 endonuclease-mediated mutation, gene ID: 56424) C57BL/6J-
Stub1<em1Schiz> (MGI: 5883536)). For this line, knockin mice are delineated (CHIPM247/M247) 
and control animals are age and sex matched wildtype littermate controls (referred to as 
CHIPT247/T247). Off-target analysis: For off-target analysis, guide RNAs were checked for 
predicted off-target sites using the web server crispr.mit.edu. The top 10 predicted off-target 
sites were PCR amplified from the founder biopsy DNA and PCR products were sequenced to 
detect the presence of mutations at each off-target site. Mutations were detected based on the 
presence of multiple peaks in the sequence traces.  
CHIP gene modified mice kidney sample preparation. Kidneys were homogenized in ice-
cold isolation solution (250 mM sucrose, 10 mM triethanolamine, pH 7.6, containing the 
protease inhibitors leupeptin (1 mg/ml) and Pefa-block (0.1 mg/ml) (Roche Applied Science) and 
phosphatase inhibitor mixture tablets (PhosSTOP, Roche Diagnostics A/S)) for generation of 
SDS-PAGE gel samples. 
Water intake analysis and plasma and urine collection in CHIP mouse models. CHIP-/- 
or CHIPM247/M247 and their respective wild-type controls were used to measure water intake 
and plasma and urine osmolalities. Animals were housed in individual cages on a 12/12 
light/dark cycle with free access to standard rodent chow (Teklad) and water. We used 
CHIP-/- and CHIPM247/M247 mice with their respective wild-type controls, balanced for sex and 
age (average age of 5.5 mo, range 3 mo - 9 mo, n = 7 - 8 mice per genotype). For 
daily water intake measurements, mice were moved to a procedure room isolated from 
outside interference to minimize accidental water loss. Three cages with no mice were 
manipulated in the same manner and used to control for water loss due to evaporation or 
spilling due to handling. The initial weight of the water bottles was measured and then at the 
same time for three consecutive days thereafter. Daily water intake was calculated 
assuming density of water = 1 g/ml. 
Spontaneous urines were collected from the same cohort of mice towards the end of the light 
cycle on three consecutive days for a total of three collections per mouse. Mice were held 
individually above a piece of parafilm until spontaneous voiding occurred (usually within 1 min). 
Urine was transferred to a micro-centrifuge tube and frozen at -20oC. Urine was centrifuged at 
12,000 g for 10 min to remove precipitates before analysis. Mice were euthanized by way of 
carbon dioxide asphyxiation with a secondary method of vital organ collection. Blood plasma 
was prepared by collecting blood in BD Microtainer SST tubes (REF 365967). Urine and plasma 
osmolalities were measured using an Advanced Wide-Range Osmometer 3W2 (Advanced 
Instruments Inc., MA, USA). Sodium, potassium, chloride, urea and creatinine concentrations 
were measured in urine and plasma samples by the Clinical Pathology Laboratory at the 
Medical Research Council (Harwell, Oxfordshire, UK).  
In vitro ubiquitylation reactions. Performed as previously described 11. Briefly, 1 μM of  
bacterially-expressed Hsc70 was incubated in the presence of 2.5 μM CHIP, 1.6 μM of AQP2, 
50 nM purified Ube1 (BostonBiochem, E305), 2.5 μM purified UbcH5c (BostonBiochem, E2-627) 
and 0.25 μM ubiquitin (BostonBiochem, U100H) in 50 mM Tris pH 7.5, 600 μM DTT, 2.5 mM 
MgCl2-ATP (BostonBiochem, B20) in a total volume of 10 μl. Reactions were incubated for 1 h 
at 37 °C and stopped by 1:1 addition of 2X Laemmli sample buffer containing 5% β-
mercaptoethanol and denatured at 100°C for 5 min. Samples were separated on a 4-15% Mini-
PROTEAN® TGX Stain-Free™ Precast Gel at 150V and transferred to a PVDF membrane at 
25V for 7 min using the Trans-Blot Turbo Transfer System (Bio-Rad). The membrane was 
blocked with 5% milk for 1 h at room temperature before immunoblotting with the appropriate 
primary antibodies: rabbit anti-AQP2 1:1,000 (H7661), rat anti-HSC70 1:5,000 (Enzo, ADI-SPA-
815), mouse anti-CHIP 1:2,000 (Sigma, S1073) overnight at 4°C. Blots were then incubated for 
1 h at room temperature with anti-mouse, anti-rabbit 1:10,000 (CST, 7076S and 7074S) or anti-
rat 1:10,000 (Sigma, A5795) IgG-HRP linked secondary antibodies and were developed using 
Clarity™ Western ECL Substrate (Bio-Rad) and imaged using the EC3TM Imaging System 
(UVP). 
Statistics. For western blotting and mouse physiological recordings, data are expressed as 
mean±S.E.M. For two groups, data meeting the statistical assumptions of normality were 
assessed using an unpaired Student`s t-test. Comparisons of more than two groups were 
performed using either a one-way ANOVA or two-way repeated-measures ANOVA followed by 
Student-Newman-Keuls or Tukey’s multiple comparison tests, respectively. Significance was 
considered at P < 0.05. The researchers were not completely blinded during sample collection 
and data acquisition/analysis. 
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SIGNIFICANCE STATEMENT
The distal convoluted tubule (DCT) and cortical
collecting duct (CCD) play unique and diverse roles
inwater and electrolyte handling, but little is known
about the unique subset of regulatory proteins in
these cells. This manuscript combines proteomics
and bioinformatics to identify differentially ex-
pressed proteins in theDCTandCCDunder various
physiological stimuli. The different regulatory
proteins within each cell type likely infer their
unique transport properties. We show that one
regulatory protein highly expressed in the CCD, the
E3 ubiquitin ligase CHIP,modulates the function of
the water channel aquaporin-2 and plays a role in
renal water handling. Pharmaceutical modulation
of CHIP function could be a novel approach to treat
various water balance disorders.
